These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 32527551)

  • 1. Development of an efficient semisynthetic modification of FR901459 via a novel regioselective N, O-acyl migration.
    Makino T; Yoshimura S; Yamanaka T; Sawada M; Barrett D
    Bioorg Med Chem Lett; 2020 Jul; 30(14):127251. PubMed ID: 32527551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of ASP5286: A novel non-immunosuppressive cyclophilin inhibitor for the treatment of HCV.
    Makino T; Yoshimura S; Neya M; Yamanaka T; Sawada M; Tsujii E; Barrett D
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127308. PubMed ID: 32631528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of a novel 9-position modified second-generation anti-HCV candidate via bioconversion and semi-synthesis of FR901459.
    Makino T; Ishida J; Yamanaka T; Ohki H; Uchida M; Sawada M; Barrett D
    Bioorg Med Chem Lett; 2020 Sep; 30(18):127423. PubMed ID: 32731088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition.
    Fu J; Tjandra M; Becker C; Bednarczyk D; Capparelli M; Elling R; Hanna I; Fujimoto R; Furegati M; Karur S; Kasprzyk T; Knapp M; Leung K; Li X; Lu P; Mergo W; Miault C; Ng S; Parker D; Peng Y; Roggo S; Rivkin A; Simmons RL; Wang M; Wiedmann B; Weiss AH; Xiao L; Xie L; Xu W; Yifru A; Yang S; Zhou B; Sweeney ZK
    J Med Chem; 2014 Oct; 57(20):8503-16. PubMed ID: 25310383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the anti-hepatitis C virus effects of cyclophilin inhibitors, cyclosporin A, and NIM811.
    Goto K; Watashi K; Murata T; Hishiki T; Hijikata M; Shimotohno K
    Biochem Biophys Res Commun; 2006 May; 343(3):879-84. PubMed ID: 16564500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioconversion of FR901459, a novel derivative of cyclosporin A, by Lentzea sp. 7887.
    Sasamura S; Kobayashi M; Muramatsu H; Yoshimura S; Kinoshita T; Ohki H; Okada K; Deai Y; Yamagishi Y; Hashimoto M
    J Antibiot (Tokyo); 2015 Aug; 68(8):511-20. PubMed ID: 25783225
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SAR study of bisamides as cyclophilin a inhibitors for the development of host-targeting therapy for hepatitis C virus infection.
    Li X; Han J; Lee HW; Yoon YS; Jin Y; Khadka DB; Yang S; Kim M; Cho WJ
    Bioorg Med Chem; 2020 Oct; 28(19):115679. PubMed ID: 32912430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Suppression of hepatitis C virus replication by cyclosporin a is mediated by blockade of cyclophilins.
    Nakagawa M; Sakamoto N; Tanabe Y; Koyama T; Itsui Y; Takeda Y; Chen CH; Kakinuma S; Oooka S; Maekawa S; Enomoto N; Watanabe M
    Gastroenterology; 2005 Sep; 129(3):1031-41. PubMed ID: 16143140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From chemical tools to clinical medicines: nonimmunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds.
    Sweeney ZK; Fu J; Wiedmann B
    J Med Chem; 2014 Sep; 57(17):7145-59. PubMed ID: 24831536
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chemical genetics approach to hepatitis C virus replication: cyclophilin as a target for anti-hepatitis C virus strategy.
    Watashi K; Shimotohno K
    Rev Med Virol; 2007; 17(4):245-52. PubMed ID: 17299803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophilin inhibitors.
    Gallay PA
    Clin Liver Dis; 2009 Aug; 13(3):403-17. PubMed ID: 19628157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design and Synthesis of Cajanine Analogues against Hepatitis C Virus through Down-Regulating Host Chondroitin Sulfate N-Acetylgalactosaminyltransferase 1.
    Ji XY; Chen JH; Zheng GH; Huang MH; Zhang L; Yi H; Jin J; Jiang JD; Peng ZG; Li ZR
    J Med Chem; 2016 Nov; 59(22):10268-10284. PubMed ID: 27783522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synthesis and biological evaluation of [D-lysine]8cyclosporin A analogs as potential anti-HCV agents.
    Scribner A; Houck D; Huang Z; Mosier S; Peel M; Scorneaux B
    Bioorg Med Chem Lett; 2010 Nov; 20(22):6542-6. PubMed ID: 20943390
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple cyclophilins involved in different cellular pathways mediate HCV replication.
    Gaither LA; Borawski J; Anderson LJ; Balabanis KA; Devay P; Joberty G; Rau C; Schirle M; Bouwmeester T; Mickanin C; Zhao S; Vickers C; Lee L; Deng G; Baryza J; Fujimoto RA; Lin K; Compton T; Wiedmann B
    Virology; 2010 Feb; 397(1):43-55. PubMed ID: 19932913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of Novel Small Molecule Anti-HCV Agents via the CypA Inhibitory Mechanism Using O-Acylation-Directed Lead Optimization.
    Yan W; Qing J; Mei H; Mao F; Huang J; Zhu J; Jiang H; Liu L; Zhang L; Li J
    Molecules; 2015 Jun; 20(6):10342-59. PubMed ID: 26053489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a cyclosporin A derivative with excellent anti-hepatitis C virus potency.
    Fu J; Becker C; Cao L; Capparelli M; Denay R; Fujimoto R; Gai Y; Gao Z; Guenat C; Karur S; Kim H; Li W; Li X; Li W; Lochmann T; Lu A; Lu P; Luneau A; Meier N; Mergo W; Ng S; Parker D; Peng Y; Riss B; Rivkin A; Roggo S; Schroeder H; Schuerch F; Simmons RL; Sun F; Sweeney ZK; Tjandra M; Wang M; Wang R; Weiss AH; Wenger N; Wu Q; Xiong X; Xu S; Xu W; Yifru A; Zhao J; Zhou J; Zürcher C; Gallou F
    Bioorg Med Chem; 2018 Feb; 26(4):957-969. PubMed ID: 28919180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclophilin Inhibitors Remodel the Endoplasmic Reticulum of HCV-Infected Cells in a Unique Pattern Rendering Cells Impervious to a Reinfection.
    Chatterji U; Bobardt M; Schaffer L; Wood M; Gallay PA
    PLoS One; 2016; 11(7):e0159511. PubMed ID: 27442520
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Augmented photoswitching modulates immune signaling.
    Zhang Y; Erdmann F; Fischer G
    Nat Chem Biol; 2009 Oct; 5(10):724-6. PubMed ID: 19734911
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle.
    Mackman RL; Steadman VA; Dean DK; Jansa P; Poullennec KG; Appleby T; Austin C; Blakemore CA; Cai R; Cannizzaro C; Chin G; Chiva JC; Dunbar NA; Fliri H; Highton AJ; Hui H; Ji M; Jin H; Karki K; Keats AJ; Lazarides L; Lee YJ; Liclican A; Mish M; Murray B; Pettit SB; Pyun P; Sangi M; Santos R; Sanvoisin J; Schmitz U; Schrier A; Siegel D; Sperandio D; Stepan G; Tian Y; Watt GM; Yang H; Schultz BE
    J Med Chem; 2018 Nov; 61(21):9473-9499. PubMed ID: 30074795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of cellular and viral factors related to anti-hepatitis C virus activity of cyclophilin inhibitor.
    Goto K; Watashi K; Inoue D; Hijikata M; Shimotohno K
    Cancer Sci; 2009 Oct; 100(10):1943-50. PubMed ID: 19659609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.